Co‐Delivery of 131 I and Prima‐1 by Self‐Assembled CD44‐Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics

2020 ◽  
pp. 2001029
Author(s):  
Shuo Huang ◽  
Linlin Zhang ◽  
Miaomiao Xu ◽  
Chao Li ◽  
Hongliang Fu ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Targeted Nanoparticles ◽  
Self Assembled

Protocol for the multimodal treatment of undifferentiated (anaplastic) thyroid carcinoma

2015 ◽  
Vol 122 (03) ◽  
Author(s):  
V Tiedje ◽  
M Kroiß ◽  
K Lorenz ◽  
S Ting ◽  
M Stuschke ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Multimodal Treatment ◽  
Anaplastic Thyroid Carcinoma

Anaplastic thyroid carcinoma: The failure of conventional therapy but the real promise of targeted therapy

2015 ◽  
Author(s):  
Paul Lennon ◽  
Sandra Deady ◽  
Marie-Louise Healy ◽  
John Kinsella ◽  
Conrad Timon ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Thyroid Carcinoma ◽  
Conventional Therapy ◽  
Anaplastic Thyroid Carcinoma ◽  
The Real

The coexistence of anaplastic thyroid carcinoma and papillary thyroid carcinoma: two case reports

2014 ◽  
Author(s):  
Husniye Baser ◽  
Mina Gulfem Kaya ◽  
Sefika Burcak Polat ◽  
Ersin Gurkan Dumlu ◽  
Canan Altunkaya ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Case Reports ◽  
Anaplastic Thyroid Carcinoma ◽  
Papillary Thyroid

Evaluation of E-Cadherin and β-Catenin Immunoreactivity for Determining Undifferentiated Cells in Anaplastic Thyroid Carcinoma

Pathobiology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Risa Kanematsu ◽  
Mitsuyoshi Hirokawa ◽  
Aki Tanaka ◽  
Ayana Suzuki ◽  
Miyoko Higuchi ◽  
...  
Keyword(s):  
Cell Membrane ◽  
Thyroid Carcinoma ◽  
Undifferentiated Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Carcinoma Cells ◽  
Membrane Expression ◽  
Thyroid Carcinomas ◽  
Nuclear Expression ◽  
Thyroid Transcription Factor 1 ◽  
E Cadherin

<b><i>Introduction:</i></b> An immunohistochemical study has occasionally been performed to diagnose anaplastic thyroid carcinoma (ATC). However, antibodies to confirm the undifferentiated nature of ATC have not yet been evaluated. The aim of this study was to evaluate E-cadherin and β-catenin expressions in immunoreactivity to determine undifferentiated carcinoma cells in the diagnosis of ATC. <b><i>Methods:</i></b> We immunohistochemically examined 29 ATCs, 30 poorly differentiated thyroid carcinomas (PDTCs), 22 well-differentiated thyroid carcinomas (WDTCs), and 3 squamous cell carcinomas. Antibodies for thyroid transcription factor-1 (TTF-1), paired-box gene 8 (PAX8), β-catenin, and E-cadherin were used. <b><i>Results:</i></b> All WDTCs tested positive for TTF-1, PAX8, and E-cadherin. The positive rates of TTF-1, PAX8, and E-cadherin were 93.3, 93.3, and 100%, respectively, in PDTCs and 17.2, 51.7, and 10.3%, respectively, in ATCs. WDTC expressed the lateral cell membrane staining for β-catenin and E-cadherin, whereas PDTC showed circumferential cell membranous expression (fishnet pattern). β-catenin cell membrane expression in ATCs is lost or discontinuous. Carcinoma cells with β-catenin nuclear expression without cell membranous expression were scattered in 72.4% of ATCs but were not observed in the other carcinomas. <b><i>Conclusion:</i></b> We propose 3 immunohistochemical findings to determine undifferentiated carcinoma cells in the diagnosis of ATC: (1) β-catenin nuclear expression with no or reduced cell membranous expression, (2) the loss or discontinuous pattern of E-cadherin expression, and (3) the loss of PAX8 nuclear expression.

Sign in / Sign up

Export Citation Format

Share Document